Influenza vaccination in immunocompromised patients: efficacy and safety - PubMed (original) (raw)
Review
Influenza vaccination in immunocompromised patients: efficacy and safety
Delphine Zbinden et al. Immunotherapy. 2014.
Abstract
Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection, as well as the immunogenicity and safety of the influenza vaccine in HIV‑infected individuals, solid-organ and stem-cell transplant recipients and patients receiving biological agents. Epidemiological data produced during the 2009 influenza pandemic have confirmed that immunocompromised patients remain at high risk of influenza-associated complications, namely viral and bacterial pneumonia, hospitalization and even death. The immunogenicity of the influenza vaccine is overall reduced in immunocompromised patients, although a significant clinical protection from influenza is expected to be obtained with vaccination. Influenza vaccination is safe in immunocompromised patients. The efficacy of novel strategies to improve the immunogenicity to the vaccine, such as the use of adjuvanted vaccines, boosting doses and intradermal vaccination, needs to be validated in appropriately powered clinical trials.
Similar articles
- Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H. Lagler H, et al. Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29. Vaccine. 2011. PMID: 21803100 - Influenza vaccination in solid-organ transplant recipients.
Cordero E, Manuel O. Cordero E, et al. Curr Opin Organ Transplant. 2012 Dec;17(6):601-8. doi: 10.1097/MOT.0b013e3283592622. Curr Opin Organ Transplant. 2012. PMID: 23042206 Review. - Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
Morelon E, Pouteil Noble C, Daoud S, Cahen R, Goujon-Henry C, Weber F, Laurent PE, Kaiserlian D, Nicolas JF. Morelon E, et al. Vaccine. 2010 Oct 4;28(42):6885-90. doi: 10.1016/j.vaccine.2010.08.015. Epub 2010 Aug 13. Vaccine. 2010. PMID: 20709000 Clinical Trial. - Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
Caldera F, Mercer M, Samson SI, Pitt JM, Hayney MS. Caldera F, et al. Vaccine. 2021 Mar 15;39 Suppl 1:A15-A23. doi: 10.1016/j.vaccine.2020.11.037. Epub 2021 Jan 7. Vaccine. 2021. PMID: 33422377 Review. - Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B. Le Corre N, et al. Vaccine. 2012 Dec 14;30(52):7522-8. doi: 10.1016/j.vaccine.2012.10.047. Epub 2012 Oct 25. Vaccine. 2012. PMID: 23103195 Clinical Trial.
Cited by
- Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations.
Hendy DA, Pena ES, Ontiveros-Padilla L, Dixon TA, Middleton DD, Williamson GL, Lukesh NR, Simpson SR, Stiepel RT, Islam MJ, Carlock MA, Ross TM, Bachelder EM, Ainslie KM. Hendy DA, et al. Bioeng Transl Med. 2023 Dec 8;9(2):e10634. doi: 10.1002/btm2.10634. eCollection 2024 Mar. Bioeng Transl Med. 2023. PMID: 38435811 Free PMC article. - Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024.
Zhu S, Quint J, León TM, Sun M, Li NJ, Tenforde MW, Jain S, Schechter R, Hoover C, Murray EL. Zhu S, et al. MMWR Morb Mortal Wkly Rep. 2024 Feb 29;73(8):175-179. doi: 10.15585/mmwr.mm7308a4. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38421946 Free PMC article. - Predictors of Severity of Influenza-Related Hospitalizations: Results From the Global Influenza Hospital Surveillance Network (GIHSN).
Cohen LE, Hansen CL, Andrew MK, McNeil SA, Vanhems P, Kyncl J, Domingo JD, Zhang T, Dbaibo G, Laguna-Torres VA, Draganescu A, Baumeister E, Gomez D, Raboni SM, Giamberardino HIG, Nunes MC, Burtseva E, Sominina A, Medić S, Coulibaly D, Salah AB, Otieno NA, Koul PA, Unal S, Tanriover MD, Mazur M, Bresee J, Viboud C, Chaves SS. Cohen LE, et al. J Infect Dis. 2024 Apr 12;229(4):999-1009. doi: 10.1093/infdis/jiad303. J Infect Dis. 2024. PMID: 37527470 Free PMC article. - Influenza vaccine coverage in 6months-64 years-old patients affected by chronic diseases: A retrospective cohort study in Italy.
Bianchi FP, Stefanizzi P, Cuscianna E, Di Lorenzo A, Migliore G, Tafuri S, Germinario CA. Bianchi FP, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2162301. doi: 10.1080/21645515.2022.2162301. Epub 2023 Jan 30. Hum Vaccin Immunother. 2023. PMID: 36715009 Free PMC article. - Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P; STAR SIGN Study Investigators; Friedrich M, Misselwitz B, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28. Aliment Pharmacol Ther. 2023. PMID: 36307899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical